Sandip Agarwala

Endeavor BioMedicines is a clinical stage company targeting the drivers of fibrosis and oncology. We combine best-in-class therapeutics with an evolving understanding of terminal diseases to develop medicines with the potential to reverse severe health conditions. Our lead program, ENV-101, is a Hedgehog signaling inhibitor with demonstrated clinical activity that we are investigating in IPF. At Endeavor, we are an innovative and focused team that has come together to live up to our name and bold mission: to help patients feel better and live longer.

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimers disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.

Beware of Job Scams: As of October 12, 2023, Talaris does not have any active job openings, and we are not conducting any hiring processes. If you come across a job posting claiming to be from Talaris, it is unauthorized and likely a scam. Please note: Talaris will never ask for your financial information in the context of job applications. Be cautious and refrain from providing such details to anyone falsely claiming to be a recruiter on behalf of Talaris.

Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data generated during a rigorous de-risking process enables formation of stand-alone companies and strategic partnerships.

We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.

We are a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system, starting with painful diabetic neuropathy, fibromyalgia, PTSD and Parkinson’s cognitive impairment. We have a proven platform for discovering proprietary compounds that works through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. Our goal is to rapidly advance our pipeline of novel clinical candidates to treat indications with high unmet medical need. At Aptinyx, we remain committed and responsive to our employees. We offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. If you are interested in learning more about our company or rewarding career opportunities, please visit our website at www.aptinyx.com or follow us on Twitter @Aptinyx

Life Science Cares (LSC) is a collective effort of the life science industry connecting companies with nonprofits that improve the lives of people living in poverty. LSC harnesses the sector’s human and financial resources from companies and supports a portfolio of 27 nonprofit organizations. LSC’s partner organizations work to address basic survival needs like food and shelter, improve education, and develop job skills that increase long-term economic sustainability for the community’s most vulnerable neighbors. For more information, visit www.lifesciencecares.org.

Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives®. With over $307 billion in assets under management as of December 31, 2025, we invest across three multi-strategy platforms: Credit, Real Assets and GP Strategic Capital. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation. Together with approximately 1,365 experienced professionals globally, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit www.blueowl.com. Social Media Disclaimers https://www.blueowl.com/social-media-disclaimers

Endeavor BioMedicines is a clinical stage company targeting the drivers of fibrosis and oncology. We combine best-in-class therapeutics with an evolving understanding of terminal diseases to develop medicines with the potential to reverse severe health conditions. Our lead program, ENV-101, is a Hedgehog signaling inhibitor with demonstrated clinical activity that we are investigating in IPF. At Endeavor, we are an innovative and focused team that has come together to live up to our name and bold mission: to help patients feel better and live longer.

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimers disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.